Sarepta Therapeutics (NASDAQ:SRPT) had its price objective boosted by Morgan Stanley from $165.00 to $220.00 in a report issued on Tuesday, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock.
A number of other equities analysts have also commented on SRPT. Royal Bank of Canada lowered shares of Roku from an outperform rating to a sector perform rating and set a $90.00 price target on the stock. in a research report on Monday, July 1st. They noted that the move was a valuation call. Cowen reaffirmed a buy rating and set a $77.00 price target on shares of Centene in a research report on Sunday, March 31st. Zacks Investment Research lowered shares of Haynes International from a hold rating to a sell rating in a research report on Wednesday, May 8th. HC Wainwright set a $267.00 price objective on shares of Sarepta Therapeutics and gave the stock a buy rating in a research note on Monday, June 17th. Finally, BidaskClub upgraded shares of Misonix from a buy rating to a strong-buy rating in a research note on Wednesday, July 3rd. One research analyst has rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $206.82.
NASDAQ:SRPT opened at $156.10 on Tuesday. Sarepta Therapeutics has a 52 week low of $95.21 and a 52 week high of $165.87. The business’s 50-day simple moving average is $131.55. The company has a debt-to-equity ratio of 0.35, a quick ratio of 11.15 and a current ratio of 12.17.
In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the sale, the director now directly owns 21,717 shares in the company, valued at $2,606,040. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 6.60% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in Sarepta Therapeutics by 104.7% in the fourth quarter. Bank of New York Mellon Corp now owns 570,668 shares of the biotechnology company’s stock valued at $62,277,000 after buying an additional 291,823 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in Sarepta Therapeutics by 7.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 12,512 shares of the biotechnology company’s stock valued at $1,365,000 after buying an additional 852 shares in the last quarter. Northern Trust Corp boosted its position in Sarepta Therapeutics by 6.5% in the fourth quarter. Northern Trust Corp now owns 318,287 shares of the biotechnology company’s stock valued at $34,734,000 after buying an additional 19,473 shares in the last quarter. Great West Life Assurance Co. Can boosted its position in Sarepta Therapeutics by 7.6% in the fourth quarter. Great West Life Assurance Co. Can now owns 7,476 shares of the biotechnology company’s stock valued at $787,000 after buying an additional 528 shares in the last quarter. Finally, Bessemer Group Inc. boosted its position in Sarepta Therapeutics by 7,143.5% in the fourth quarter. Bessemer Group Inc. now owns 1,666 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 1,643 shares in the last quarter. Institutional investors own 94.36% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
See Also: Bond
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.